AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6175138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide treatment
Number of subjects: 11
Study 29506034 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐15L (Juvéderm Volbella XC)
Number of subjects: 124
Study 27824330 — intervention group
Group type: EXPERIMENTAL
Intervention: PEI-pPDGF-B polyplexes
Number of subjects: 0
Study 27824330 — intervention group
Group type: COMPARATOR
Intervention: Collagen alone
Number of subjects: 0
Study 27824330 — intervention group
Group type: COMPARATOR
Intervention: rhPDGF-BB
Number of subjects: 0
Study 27824330 — intervention group
Group type: COMPARATOR
Intervention: PEI vector
Number of subjects: 0
Study 24433244 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 24571703 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice (Oral-B(®) Pro-Expert Sensitive)
Number of subjects: 35
Study 24571703 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride/potassium nitrate dentifrice (Sensodyne(®) Pronamel(®))
Number of subjects: 35
Study 22578899 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 60
Study 22578899 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 20221984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling (group A)
Number of subjects: 41
Study 20221984 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide (TA) injection (group B)
Number of subjects: 41
Study 17564719 — intervention group
Group type: COMPARATOR
Intervention: PDT‐IVTA with standard light fluence of 50 J/cm(2) (SPDT‐IVTA)
Number of subjects: 30
Study 17564719 — intervention group
Group type: COMPARATOR
Intervention: PDT‐IVTA with reduced light fluence of 25 J/cm(2) (RPDT‐IVTA)
Number of subjects: 30
Study 17564719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 30
Study 17564719 — intervention group
Group type: COMPARATOR
Intervention: All groups (SPDT‐IVTA, RPDT‐IVTA, IVB)
Number of subjects: 30
Study 15637533 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI-779 (25, 75, or 250 mg once weekly)
Number of subjects: 50
Study 11802924 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 1529
Study 11802924 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg once daily
Number of subjects: 1529
Study 11802924 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg twice daily
Number of subjects: 1529
Study 11802924 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir
Number of subjects: 1529
Study 10233315 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) levels > 2 microgram/g of dust
Number of subjects: 41
Study 10233315 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) levels between 0.1 and 2 microgram/g of dust
Number of subjects: 41
Study 10233315 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) levels < 0.1 microgram/g of dust
Number of subjects: 41
Study 7813329 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary pulmonary embolism thrombolysis
Number of subjects: 0
Study 2551242 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder form of ADM, MMC, and CDDP suspended in lipiodol
Number of subjects: 0
Study 2551242 — intervention group
Group type: EXPERIMENTAL
Intervention: URO form of ADM and MMC dissolved with Urografin mixed with lipiodol
Number of subjects: 0
Study 2551242 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological saline water form of ADM and MMC
Number of subjects: 0
Study 2551242 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP solution as usually used
Number of subjects: 0
Study 2551242 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder form of CDDP
Number of subjects: 0
Study 1217693 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 1217693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalorphine
Number of subjects: 0
Study 1217693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30794314 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut patch containing 250 μg of peanut protein (n=238)
Number of subjects: 356
Study 30794314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=118)
Number of subjects: 356
Study 28612995 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 5
Study 28612995 — intervention group
Group type: COMPARATOR
Intervention: In-clinic follow-up
Number of subjects: 5
Study 26304464 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.0 g/day)
Number of subjects: 193
Study 26304464 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 g/day)
Number of subjects: 193
Study 26304464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 23695657 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Lutein, 1 mg Zeaxanthin, 100 mg DHA, 30 mg EPA, antioxidants (D1)
Number of subjects: 172
Study 23695657 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Lutein, 1 mg Zeaxanthin, 100 mg DHA, 30 mg EPA, antioxidants (D2)
Number of subjects: 172
Study 23695657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 172
Study 21270185 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day or 100 mg/day)
Number of subjects: 2523
Study 21270185 — intervention group
Group type: COMPARATOR
Intervention: Nonaspirin
Number of subjects: 2523
Study 19922256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud therapy (topical gel prepared using Lake Urmia mud)
Number of subjects: 50
Study 19922256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23141953 — intervention group
Group type: COMPARATOR
Intervention: Cervical artificial insemination (CAI): 3×10(9) spermatozoa/80 ml
Number of subjects: 0
Study 23141953 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 1): 1.5×10(9) spermatozoa/40 ml
Number of subjects: 0
Study 23141953 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 2): 1×10(9) spermatozoa/26 ml
Number of subjects: 0
Study 23141953 — intervention group
Group type: COMPARATOR
Intervention: Cervical artificial insemination (CAI)
Number of subjects: 0
Study 23141953 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 1)
Number of subjects: 0
Study 23141953 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 2)
Number of subjects: 0
Study 15765197 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise program (mainly resistance training) for six months
Number of subjects: 95
Study 15765197 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 95
Study 12538174 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 50 (BIS level 45-55)
Number of subjects: 62
Study 12538174 — intervention group
Group type: COMPARATOR
Intervention: BIS 40 (BIS level 35-45)
Number of subjects: 62
Study 12538174 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 50
Number of subjects: 62
Study 12538174 — intervention group
Group type: COMPARATOR
Intervention: BIS 40
Number of subjects: 62
Study 12538174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 9819168 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP: 2 mg.kg(‐1) body weight)
Number of subjects: 7
Study 9819168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL: maltodextrin capsule)
Number of subjects: 7
Study 9819168 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 7
Study 9819168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study 8583101 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA (Claversal), 0.5 g b.i.d.
Number of subjects: 88
Study 8583101 — intervention group
Group type: COMPARATOR
Intervention: SASP, 1 g b.i.d.
Number of subjects: 88
Study 8583101 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA and SASP
Number of subjects: 88
Study 2642669 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 750 mg daily
Number of subjects: 60
Study 2642669 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 60
Study 791307 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 100 mg
Number of subjects: 75
Study 791307 — intervention group
Group type: COMPARATOR
Intervention: suxethonium 150 mg
Number of subjects: 75
Study 11589838 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T determinations
Number of subjects: 856
Study 11589838 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation (controls)
Number of subjects: 856
Study 30904248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 0
Study 30904248 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen
Number of subjects: 0
Study 30256548 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy
Number of subjects: 116
Study 30256548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 116
Study 30256548 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation training
Number of subjects: 116
Study 26254169 — intervention group
Group type: COMPARATOR
Intervention: BCS (Breast-Conserving Surgery)
Number of subjects: 75
Study 26254169 — intervention group
Group type: EXPERIMENTAL
Intervention: BCS + M (BCS with resection of 5 additional margins)
Number of subjects: 75
Study 26254169 — intervention group
Group type: COMPARATOR
Intervention: BCS
Number of subjects: 75
Study 26254169 — intervention group
Group type: EXPERIMENTAL
Intervention: BCS + M
Number of subjects: 75
Study 24219842 — intervention group
Group type: EXPERIMENTAL
Intervention: PACCI-ED (intervention group)
Number of subjects: 77
Study 24219842 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded to PACCI-ED responses)
Number of subjects: 77
Study 22496082 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization (RMJI=0)
Number of subjects: 751
Study 22496082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly incomplete revascularization (RMJI >0≤33)
Number of subjects: 751
Study 22496082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately to severely incomplete revascularization (RMJI >33)
Number of subjects: 751
Study 20297858 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS® hydromorphone administered once daily for up to 52 weeks
Number of subjects: 0
Study 20297858 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS® hydromorphone
Number of subjects: 0
Study 18607594 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 M gadobutrol
Number of subjects: 471
Study 18607594 — intervention group
Group type: COMPARATOR
Intervention: 0.5 M gadopentate dimeglumine
Number of subjects: 471
Study 15814078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment program for anxiety disorder (12-week duration)
Number of subjects: 23
Study 15814078 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 23
Study 11923558 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 12
Study 11923558 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine capsule (200 mg)
Number of subjects: 12
Study 11923558 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 12
Study 9459251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg) with intraarticular bupivacaine (30 mL of 0.25%)
Number of subjects: 100
Study 9459251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg) with normal saline (30 mL)
Number of subjects: 100
Study 9459251 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular bupivacaine (30 mL of 0.25%)
Number of subjects: 100
Study 9459251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular bupivacaine (30 mL of 0.25%) with intravenous morphine (5 mg)
Number of subjects: 100
Study 8583231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to frontal or parietal cortex, timing at -70 msec and -20 msec before saccade onset.
Number of subjects: 0
Study 2523769 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.4 nmol min‐1 kg‐1)
Number of subjects: 16
Study 2523769 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour word conflict test (CWT)
Number of subjects: 16
Study 2523769 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study 795013 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 36
Study 795013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCI
Number of subjects: 36
Study 30580563 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum Dkk‐1 levels
Number of subjects: 3178
Study 30580563 — intervention group
Group type: EXPERIMENTAL
Intervention: Each SD increase of log-transformed Dkk‐1
Number of subjects: 3178
Study 30580563 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Dkk‐1 addition to conventional risk factors
Number of subjects: 3178
Study 28426885 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 755
Study 28426885 — intervention group
Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 755
Study 25284643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus(®) 6 SCAN (activating SNR‐NR)
Number of subjects: 30
Study 25284643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus(®) 6 SCAN
Number of subjects: 30
Study 25284643 — intervention group
Group type: COMPARATOR
Intervention: Nucleus(®) 6 and Nucleus(®) 5
Number of subjects: 30
Study 25284643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus(®) 5 to Nucleus(®) 6 conversion
Number of subjects: 30
Study 23743714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangerous graspable objects
Number of subjects: 0
Study 23743714 — intervention group
Group type: COMPARATOR
Intervention: Neutral graspable objects
Number of subjects: 0
Study 23743714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ungraspable objects (both dangerous and neutral)
Number of subjects: 0
Study 21272338 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW (resistance exercise via negative eccentrically-induced work) for 12 weeks
Number of subjects: 40
Study 19218125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled pen
Number of subjects: 184
Study 19218125 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 184
Study 16968715 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 356
Study 16968715 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 356
Study 16968715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 16968715 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly and 25 mg twice weekly
Number of subjects: 356
Study 14618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved shaft catheters (2 new and 1 standard)
Number of subjects: 29
Study 14618054 — intervention group
Group type: COMPARATOR
Intervention: Straight shaft catheters
Number of subjects: 29
Study 14618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of curved and straight shaft catheters
Number of subjects: 29
Study 10753829 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (3 microg/kg, single bolus subcutaneous injection)
Number of subjects: 0
Study 10753829 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 0
Study 8795757 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 83
Study 8795757 — intervention group
Group type: COMPARATOR
Intervention: Control group (not on CCB)
Number of subjects: 83
Study 1617888 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy
Number of subjects: 0
Study 6235685 — intervention group
Group type: EXPERIMENTAL
Intervention: spectinomycin
Number of subjects: 176
Study 6235685 — intervention group
Group type: COMPARATOR
Intervention: penicillin G
Number of subjects: 176
Study 30772471 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated asthma community health workers (CHW) home visits
Number of subjects: 223
Study 30772471 — intervention group
Group type: COMPARATOR
Intervention: Certified asthma educator (AE‐C) education in the clinic
Number of subjects: 223
Study 29889057 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted sit-up exercise (SUE) using HubEX-LEX®
Number of subjects: 36
Study 29889057 — intervention group
Group type: COMPARATOR
Intervention: Conventional core stabilization exercise (CSE)
Number of subjects: 36
Study 27341795 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (CBP group, n=48)
Number of subjects: 94
Study 27341795 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus nedaplatin (NDP group, n=46)
Number of subjects: 94
Study 27341795 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of chemotherapy
Number of subjects: 94
Study 27341795 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy scheme
Number of subjects: 94
Study 27341795 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and pathological type
Number of subjects: 94
Study 23676337 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month Internet-based intervention promoting physical activity
Number of subjects: 536
Study 22907974 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m² i.v. for 100 minutes on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 90
Study 22907974 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Docetaxel (Gemcitabine 900 mg/m² i.v. for 90 minutes on days 1 and 8, plus Docetaxel 100 mg/m² i.v. for 1 hour on day 8 of a 21-day cycle with lenograstim)
Number of subjects: 90
Study 20081039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg three times per day
Number of subjects: 80
Study 20081039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg three times per day
Number of subjects: 80
Study 20081039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20081039 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (gabapentin and placebo)
Number of subjects: 80
Study 18076806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with concurrent radiotherapy (400 mg/m(2) weekly, total radiotherapy dose of 60-66 Gy)
Number of subjects: 60
Study 18076806 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (total dose of 60-66 Gy)
Number of subjects: 60
Study 18076806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with concurrent radiotherapy
Number of subjects: 60
Study 18076806 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 60
Study 15960096 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 0
Study 15960096 — intervention group
Group type: EXPERIMENTAL
Intervention: Earmuffs
Number of subjects: 0
Study 15960096 — intervention group
Group type: EXPERIMENTAL
Intervention: Double hearing protection (earplugs and earmuffs simultaneously)
Number of subjects: 0
Study 15960096 — intervention group
Group type: COMPARATOR
Intervention: No hearing protection
Number of subjects: 0
Study 15960096 — intervention group
Group type: COMPARATOR
Intervention: No auditory cue (control condition)
Number of subjects: 0
Study 12131602 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava kava (Piper methysticum)
Number of subjects: 37
Study 12131602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10474848 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 124
Study 10474848 — intervention group
Group type: COMPARATOR
Intervention: No-therapy control group
Number of subjects: 124
Study 8942598 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BronchoCath double-lumen tube (DLT)
Number of subjects: 40
Study 8942598 — intervention group
Group type: COMPARATOR
Intervention: Univent tube with bronchial blocker
Number of subjects: 40
Study 1757243 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pyridostigmine
Number of subjects: 25
Study 1757243 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pyridostigmine
Number of subjects: 25
Study 1757243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6126145 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% intranasal sodium cromoglycate solution
Number of subjects: 47
Study 6126145 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study 31634258 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational video on MMS in addition to traditional informed consent
Number of subjects: 231
Study 31634258 — intervention group
Group type: COMPARATOR
Intervention: Informed consent without video viewing (Control)
Number of subjects: 231
Study 29803404 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Unit Number Index (MUNIX) measurement
Number of subjects: 36
Study 29803404 — intervention group
Group type: EXPERIMENTAL
Intervention: MUNIX
Number of subjects: 36
Study 26084276 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat 100 mg t.i.d. + S. boulardii 500 mg b.i.d.
Number of subjects: 42
Study 26084276 — intervention group
Group type: COMPARATOR
Intervention: Miglustat 100 mg t.i.d. + placebo
Number of subjects: 42
Study 23351522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and Olanzapine
Number of subjects: 100
Study 23351522 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 100
Study 20638899 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 332
Study 20638899 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 332